{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:25:40Z","timestamp":1781688340792,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004946","name":"National Chung Hsing University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1144601B"],"award-info":[{"award-number":["TCVGH-1144601B"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bone.2025.117678","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:41:32Z","timestamp":1760560892000},"page":"117678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network"],"prefix":"10.1016","volume":"202","author":[{"given":"Tse-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Lian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Heng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Fu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Tung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chih","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2025.117678_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos. Int."},{"issue":"10","key":"10.1016\/j.bone.2025.117678_bb0010","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00198-022-06454-3","article-title":"Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis","volume":"33","author":"Xiao","year":"2022","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2025.117678_bb0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ecl.2024.08.008","article-title":"Postmenopausal Osteoporosis: A Review of Latest Guidelines","volume":"53","author":"Subarajan","year":"2024","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"8","key":"10.1016\/j.bone.2025.117678_bb0020","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bone.2025.117678_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.bone.2025.117678_bb0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00198-019-05233-x","article-title":"Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates","volume":"31","author":"Miller","year":"2020","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2025.117678_bb0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.bone.2025.117678_bb0040","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00198-021-06268-9","article-title":"Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review","volume":"33","author":"Wan","year":"2022","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117678_bb0045","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.bone.2025.117678_bb0050","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00198-024-07118-0","article-title":"Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials","volume":"35","author":"Kobayashi","year":"2024","journal-title":"Osteoporos. Int."},{"issue":"11","key":"10.1016\/j.bone.2025.117678_bb0055","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00198-021-05995-3","article-title":"Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study","volume":"32","author":"Hasegawa","year":"2021","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2025.117678_bb0060","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00198-023-06732-8","article-title":"Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan","volume":"34","author":"Kunihara","year":"2023","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.bone.2025.117678_bb0065","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00198-024-07108-2","article-title":"Key insights into antiresorptive drug use and osteonecrosis in osteoporotic patients undergoing tooth extractions: A clinical and CBCT assessment","volume":"35","author":"Moreno-Rabie","year":"2024","journal-title":"Osteoporos. Int."},{"issue":"11","key":"10.1016\/j.bone.2025.117678_bb0070","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1634\/theoncologist.2009-0115","article-title":"Bisphosphonates and time to osteonecrosis development","volume":"14","author":"Palaska","year":"2009","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.bone.2025.117678_bb0075","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"1","key":"10.1016\/j.bone.2025.117678_bb0080","first-page":"36","article-title":"Bisphosphonate-related osteonecrosis of the jaws","volume":"27","author":"Yeo","year":"2005","journal-title":"Singapore Dent. J."},{"issue":"5","key":"10.1016\/j.bone.2025.117678_bb0085","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2025.117678_bb0090","article-title":"The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bone.2025.117678_bb0095","article-title":"The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: A 12-year retrospective study of 129 patients","volume":"14","author":"Kaibuchi","year":"2021","journal-title":"Bone Rep"},{"issue":"7","key":"10.1016\/j.bone.2025.117678_bb0100","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"7","author":"Beth-Tasdogan","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"26","key":"10.1016\/j.bone.2025.117678_bb0105","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial","volume":"38","author":"Sim","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.bone.2025.117678_bb0110","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMc1002684","article-title":"Teriparatide therapy for alendronate-associated osteonecrosis of the jaw","volume":"363","author":"Cheung","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bone.2025.117678_bb0115","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hed.21380","article-title":"Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy","volume":"33","author":"Lee","year":"2011","journal-title":"Head Neck"},{"issue":"5","key":"10.1016\/j.bone.2025.117678_bb0120","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00198-014-2622-8","article-title":"Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw","volume":"25","author":"Kim","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"12","key":"10.1016\/j.bone.2025.117678_bb0125","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/jbmr.3237","article-title":"Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study","volume":"32","author":"Jung","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2025.117678_bb0130","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2013-4119","article-title":"The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene","volume":"99","author":"Chiu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2025.117678_bb0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2025.117678_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.bone.2025.117678_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"9768","key":"10.1016\/j.bone.2025.117678_bb0150","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bone.2025.117678_bb0155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bone.2025.117678_bb0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","article-title":"Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study","volume":"30","author":"Hasegawa","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117678_bb0165","first-page":"172","article-title":"The effect of denosumab vs. zoledronic acid in preventing skeletal-related events, including pain-related bone metastasis: a systematic review","volume":"33","author":"Widyadharma","year":"2024","journal-title":"Postep Psychiatr Neurol"},{"key":"10.1016\/j.bone.2025.117678_bb0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"16","key":"10.1016\/j.bone.2025.117678_bb0175","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.bone.2025.117678_bb0180","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bone.2025.117678_bb0185","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s00198-022-06544-2","article-title":"Romosozumab efficacy and safety in European patients enrolled in the FRAME trial","volume":"33","author":"Langdahl","year":"2022","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822500290X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822500290X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:28:55Z","timestamp":1780558135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822500290X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"alternative-id":["S875632822500290X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117678","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-related osteonecrosis of the jaw following osteoporosis therapy: A real-world retrospective cohort study using the TriNetX global collaborative network","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117678"}}